Treatment of IgA Nephropathy

Source: Seminars in Nephrology. 20(3): 277-285. May 2000.

Contact: Available from W.B. Saunders Company. Periodicals Department. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452.

Summary: IgA nephropathy (Berger's disease) is the most common primary glomerulonephritis (infection of the kidney glomeruli) worldwide and was once equated with benign recurrent hematuria (blood in the urine). This article reviews the patient care management of IgA nephropathy. Of the patient population with IgA nephropathy, 15 to 30 percent progress to end stage renal failure after 20 years of clinical manifestations. Because the pathogenesis remains enigmatic, therapy to slow disease progression cannot be disease specific. Control of blood pressure remains the cornerstone of treatment, as for patients with other types of kidney disease. Several approaches to treatment have generated increasing interest in the last few years, including angiotensin inhibition, glucocorticoids, fish oil, cyclophosphamide, tonsillectomy, and mycophenolate mofetil. For patients reaching end stage renal failure, recurrent disease after transplantation can be a clinically important problem (even in light of continued immunosuppression after the transplantation). 2 figures. 65 references.

0 0

Post a comment